More than a year after it was approved for adults and children 12 years and older, Arcutis Biotherapeutics’ steroid-free topical cream for plaque psoriasis is now available for younger kids.
The FDA has approved Zoryve (roflumilast) for children as young as 6, Arcutis announced Friday. The company tested Zoryve specifically in skin folds for this population, where psoriasis is more likely to occur compared with adults. Arcutis touts the drug as a non-greasy, fast-absorbing — and importantly, steroid-free — option for young kids.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.